Why TB programmes should assess for comorbidities, determinants and disability at the start and end of TB treatment

Int J Tuberc Lung Dis. 2023 Jul 1;27(7):495-498. doi: 10.5588/ijtld.23.0178.
No abstract available

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Comorbidity
  • Humans
  • Tuberculosis, Pulmonary* / epidemiology

Substances

  • Antitubercular Agents